Jul 27, 2006 by Brian LawlerSerono Under AttackThe pharma lacks a strong pipeline, and competition is heating up.
Jul 27, 2006 by Brian LawlerGood Quarter for VertexA new agreement and good news on a promising drug spell success for Vertex.
Jul 25, 2006 by Brian LawlerStrike Two for EncysiveThe FDA still won't quite give Thelin a thumbs-up.
Jul 21, 2006 by Brian LawlerAmgen's Little HelpersSluggish earnings are offest by promising drugs in the pipeline.
Jul 21, 2006 by Brian LawlerSepracor Stays AlertInsomnia drug Lunesta's sales growth is anything but sleepy.
Jul 20, 2006 by Brian LawlerCubist's Square ResultsThe pharmaceutical company has a promising new drug, but little else in the pipeline.
Jul 20, 2006 by Brian LawlerMedImmune Is Easy to ResistDespite the prospects from sales of two new vaccines, it's hard to feel better about this stock.
Jul 20, 2006 by Brian LawlerNo Surprises From ImCloneImClone's lead product experienced strong revenue growth in the second quarter.
Jul 18, 2006 by Brian LawlerNeurocrine's Tale of WoeAfter a couple of tough months, Neurocrine released its second-quarter results.
Jul 12, 2006 by Brian LawlerGenzyme Continues to DeliverThe biopharmaceutical company releases their quarter two earnings announcement.
Jul 10, 2006 by Brian LawlerCV Therapeutics Gets GreenlightedA final trial could secure full FDA approval for angina drug Ranexa.
Jul 10, 2006 by Brian LawlerNorthfield Frowns on Focus From "20/20"The maker of artificial blood finds yet another critic.
Jul 6, 2006 by Brian LawlerCephalon on the HuntThe biopharma company is looking to make more acquisitions and gets some good news from the FDA.
Jul 5, 2006 by Brian LawlerStay Away From QLTCompetitive pressure on its top drug makes this company one to avoid.
Jun 27, 2006 by Brian LawlerCephalon Stays BusyGabitril's phase 3 failure isn't the end of the drugmaker's prospects.
Jun 6, 2006 by Brian LawlerExelixis' Continued ExcellenceThe company reported preliminary phase 1 results for three of its lead compounds.
Jun 2, 2006 by Brian LawlerEncysive Can Breathe EasierThe pharmaceutical's crucial Thelin drug gains EU approval.
